Smith & Nephew Future Growth

Future criteria checks 3/6

Smith & Nephew is forecast to grow earnings and revenue by 21.2% and 5% per annum respectively. EPS is expected to grow by 22.6% per annum. Return on equity is forecast to be 16.6% in 3 years.

Key information

21.2%

Earnings growth rate

22.6%

EPS growth rate

Medical Equipment earnings growth	16.1%
Revenue growth rate	5.0%
Future return on equity	16.6%
Analyst coverage	Good
Last updated	18 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NYSE:SNN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	6,456	791	782	1,264	12
12/31/2025	6,131	703	719	1,143	17
12/31/2024	5,831	549	567	1,014	17
12/31/2023	5,549	263	181	608	N/A
9/30/2023	5,449	241	102	491	N/A
7/1/2023	5,349	218	22	374	N/A
4/1/2023	5,282	221	66	421	N/A
12/31/2022	5,215	223	110	468	N/A
9/30/2022	5,214	360	213	595	N/A
7/2/2022	5,213	496	315	721	N/A
4/2/2022	5,213	510	392	799	N/A
12/31/2021	5,212	524	469	877	N/A
9/30/2021	5,168	539	632	1,051	N/A
7/3/2021	5,124	553	795	1,225	N/A
4/3/2021	4,842	501	644	1,080	N/A
12/31/2020	4,560	448	492	935	N/A
9/30/2020	4,624	420	420	863	N/A
6/27/2020	4,688	391	347	790	N/A
3/27/2020	4,913	496	554	979	N/A
12/31/2019	5,138	600	760	1,168	N/A
9/30/2019	5,044	649	762	1,127	N/A
6/29/2019	4,949	698	763	1,085	N/A
3/29/2019	4,927	681	674	1,008	N/A
12/31/2018	4,904	663	584	931	N/A
9/30/2018	4,887	690	622	984	N/A
6/30/2018	4,869	717	660	1,036	N/A
3/31/2018	4,817	742	687	1,063	N/A
12/31/2017	4,765	767	714	1,090	N/A
9/30/2017	4,721	817	N/A	1,011	N/A
7/1/2017	4,677	867	N/A	931	N/A
4/1/2017	4,673	826	N/A	890	N/A
12/31/2016	4,669	784	N/A	849	N/A
9/30/2016	4,680	570	N/A	829	N/A
7/2/2016	4,690	356	N/A	809	N/A
4/2/2016	4,662	383	N/A	920	N/A
12/31/2015	4,634	410	N/A	1,030	N/A
9/30/2015	4,702	513	N/A	1,062	N/A
6/27/2015	4,669	557	N/A	940	N/A
3/27/2015	4,680	499	N/A	837	N/A
12/31/2014	4,617	501	N/A	683	N/A
9/27/2014	4,543	503	N/A	702	N/A
6/28/2014	4,422	523	N/A	753	N/A
3/29/2014	4,349	563	N/A	766	N/A
12/31/2013	4,351	556	N/A	867	N/A
9/28/2013	4,253	534	N/A	798	N/A
6/29/2013	4,178	544	N/A	851	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNN's forecast earnings growth (21.2% per year) is above the savings rate (2.3%).

Earnings vs Market: SNN's earnings (21.2% per year) are forecast to grow faster than the US market (14.8% per year).

High Growth Earnings: SNN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SNN's revenue (5% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: SNN's revenue (5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SNN's Return on Equity is forecast to be low in 3 years time (16.6%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Smith & Nephew Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Increases Revenue Guidance for 2023

Smith & Nephew plc Announces Revenue Guidance for 2022

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Year of 2022

Smith & Nephew plc Provides Revenue Guidance for the Full Year 2021

Recent updates

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Smith & Nephew: Orthopedics Growth Continues To Drive Sales Forward

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Smith & Nephew Getting More Interesting As A Contrarian Idea

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc Increases Revenue Guidance for 2023

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Smith & Nephew: Entering New Markets But Growth Is Slow Still

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Smith & Nephew reports FY earnings; initiates FY23 guidance

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023

Smith & Nephew: Potential Only Has Value If You Can Execute

Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023

Smith & Nephew plc Announces Revenue Guidance for 2022

Smith+Nephew Expands Procedural Innovation with Introduction of JOURNEY(TM) II ROX(TM) Total Knee Solution

Smith+Nephew First to Market with Revision Knee Indication on Robotics Platform

Smith & Nephew: Still A Buy Despite Short-Term Challenges

Smith+Nephew Launches OR3O ™ Dual Mobility System in Japan for Use in Primary and Revision Hip Arthroplasty

Smith+Nephew Announces New Data Furthering a Number of Published Studies Supporting the Use of Its REGENETEN Bioinductive Implant in Rotator Cuff Repair

Smith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022

Smith &amp; Nephew 1H 2022 Earnings Preview

Smith+Nephew Launches Clinical Support App to Help Reduce Practice Variation in Wound Care

Smith+Nephew launches app Wound Compass to help reduce variation in wound care

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Announces Executive Changes

Smith+Nephew Announces First Total Hip Replacement Cases on its CORI Surgical System Using RI.HIP Modeler and RI.HIP Navigation

Smith & Nephew: Fair Price For An Attractive Medical Devices Supplier

Smith+Nephew Announces New Study Showing GRAFIX™ Membrane Cut the Rate of Diabetic Foot Ulcer Recurrence in Half Compared to Leading Competitors

Smith & Nephew plc, Annual General Meeting, Apr 13, 2022

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Year of 2022

Smith+Nephew Expands Next-Generation Handheld Robotic-Assisted CORI™ Surgical System into Total Hip Arthroplasty with RI.HIP NAVIGATION

Smith & Nephew: Valuation Looking More Attractive

Smith+Nephew Announces New Indications for Use for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy Systems

Smith & Nephew plc (LSE:SN.) acquired Engage Surgical.

Smith & Nephew plc (LSE:SN.) announces an Equity Buyback for $300 million worth of its shares.

Smith+Nephew Launches Real Intelligence and CORI Surgical System and Next Generation Handheld Robotics Platform in Canada

Smith+Nephew Launches CORI Handheld Robotics

Smith & Nephew Is A Premium Brand That Should Deliver Something Special

Smith & Nephew Leveraged To Post-Pandemic Normalization And Self-Help

Smith+Nephew Introduces Pioneering New Technologies for Its Journey II Total Knee Arthroplasty Portfolio

Smith+Nephew Announces Launch of WEREWOLF FASTSEAL 6.0 Hemostasis Wand

Smith+Nephew Announces Study Results Showing Patients Treated with Just its REGENETEN Bioinductive Implant for Partial-Thickness Rotator Cuff Tears

Smith & Nephew plc: Improving Performance Reflected In Price

Smith+Nephew Launches ARIA Home PT, a Remote Physical Therapy Solution

Smith & Nephew plc Provides Revenue Guidance for the Full Year 2021

Smith+Nephew's ALLEVYN™ LIFE Foam Dressings Halved Change Frequency, Significantly Reduced Cost and Improved Treatment Satisfaction in Real-World Study

Net Health Adds Smith+Nephew's RENASYS GO Negative Pressure Wound Therapy System to Net Health® Wound Care Connections Lineup

Smith & Nephew plc, Annual General Meeting, Apr 14, 2021

Smith & Nephew plc Announces Appointment of John Ma as Non-Executive Director, Effective 17 February 2021

Smith & Nephew: Pandemic Long Tail Reduces Attractiveness

Smith+Nephew Partners with Movemedical to Streamline Inventory Management and Improve Customer Experience

Smith & Nephew plc Confirms Retirement of Vinita Bali as Non-Executive Director

Smith & Nephew plc (LSE:SN.) completed the acquisition of Extremity Orthopedics business of Integra LifeSciences Holdings Corporation.

Smith+Nephew Announces Outstanding Clinical Results for Its Total Hip Arthroplasty Portfolio

Smith & Nephew plc to Report Q2, 2021 Results on Jul 29, 2021

Smith & Nephew: A Long-Term Buy And Hold In Medical Devices

Smith & Nephew 1H 2022 Earnings Preview